AVITA Medical, Inc. (NASDAQ: RCEL ) is a company working on a complete portfolio for full-thickness wound reconstruction. They offer RECELL and RECELL GO for point-of-care autologous “Spray-On Skin.” RCEL also has Cohealyx for graft-ready dermis, and PermeaDerm as a protective biosynthetic cover in partnershipMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from ...

AVITA Medical, Inc. (NASDAQ: RCEL ) is a company working on a complete portfolio for full-thickness wound reconstruction. They offer RECELL and RECELL GO for point-of-care autologous “Spray-On Skin.” RCEL also has Cohealyx for graft-ready dermis, and PermeaDerm as a protective biosynthetic cover in partnershipMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from ...

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - FGI Industries Ltd. (FGI) is up 278% at $15.02 [3] - Senmiao Technology Limited (AIHS) is up 96% at $4.22 [3] - Conifer Holdings, Inc. (CNFR) is up 86% at $2.11 [3] - WEBTOON Entertainment Inc. (WBTN) is up 39% at $20.81 [3] - Nukkleus Inc. (NUKK) is up 18% at $6.08 [3] - Tantech Holdings Ltd (TANH) is up 12% at $2.13 [3] - Check-Cap Ltd. (CHEK) is up 9% at $2.33 [3] - Ivanhoe Electric Inc. (IE) is up 8% at $9.71 [3] - Wolfspeed, Inc. (WOLF) is up 8% at $3.21 [3] - Bolt Projects Holdings, Inc. (BSLK) is up 5% at $3.95 [3] Premarket Losers - Envirotech Vehicles, Inc. (EVTV) is down 17% at $2.27 [4] - Dave & Buster's Entertainment, Inc. (PLAY) is down 15% at $20.40 [4] - NanoVibronix, Inc. (NAOV) is down 12% at $9.37 [4] - ADTRAN Holdings, Inc. (ADTN) is down 10% at $9.37 [4] - Rain Enhancement Technologies Holdco, Inc. (RAIN) is down 10% at $6.00 [4] - CNS Pharmaceuticals, Inc. (CNSP) is down 7% at $8.50 [4] - AVITA Medical, Inc. (RCEL) is down 7% at $6.22 [4] - Vince Holding Corp. (VNCE) is down 7% at $2.60 [4] - Monte Rosa Therapeutics, Inc. (GLUE) is down 6% at $6.50 [4] - Meiwu Technology Company Limited (WNW) is down 6% at $2.06 [4]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Avita and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential clai ...

智通财经APP获悉，皮肤修复设备开发商Avita Medical(RCEL.US)的新一代自体细胞采集设备RECELL GO系统已获得欧盟医疗器械法规(EU MDR)下CE认证。受该消息提振，截至发稿，Avita Medical周一美 股盘前涨近10%。 据悉，RECELL GO系统是一种用于采集自体细胞以治疗烧伤和皮肤缺陷的先进设备。与传统植皮相 比，RECELL具有更好的优势，例如改善愈合，减少供体皮肤使用，减轻疼痛，更快的伤口闭合，更好 的美学效果，所需的手术更少，以及某些烧伤的住院时间更短。RECELL-GO简化了皮肤细胞喷雾的制 备，减少了培训需求，提高了手术室的效率，并确保了最佳的细胞产量和活力。 Avita Medical首席执行官Jim Corbett表示："RECELL GO的CE认证对Avita Medical和患者而言都是一个 重要的里程碑。这使我们能够将这一选择带给欧洲的烧伤中心和临床医生，以支持他们治疗急性创伤患 者。" ...

Core Insights - AVITA Medical has received the CE Mark for its RECELL GO device, allowing commercialization in Europe and other CE Mark-recognizing markets [1][2] - The RECELL GO device enables healthcare professionals to prepare a suspension of a patient's own skin cells to promote healing in burns and traumatic or surgical wounds [2] - Clinical data presented at the 2025 European Burns Association Congress showed a 36% reduction in hospital stays for adults with deep partial-thickness burns treated with RECELL compared to traditional grafting [3] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on optimizing wound healing and accelerating patient recovery [5] - The RECELL System, which includes RECELL GO, is approved by the U.S. FDA for treating thermal burn and trauma wounds, utilizing a patient's own skin to create Spray-On Skin™ Cells [5][6] - In addition to RECELL, AVITA Medical holds exclusive rights to manufacture and distribute PermeaDerm and Cohealyx™, enhancing its product portfolio in wound care [5]

Sep 11, 2025 3:31 PM Eastern Daylight Time We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. RCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Avita and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 7, 2 ...

Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AVITA Medical, Inc. (“Avita” or “the Company”) (NASDAQ : RCEL) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Avita investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of AVITA Medical, Inc. ("AVITA†or the "Company†) (NASDAQ:RCEL) investors concerning the Company's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 7, 2025, AVITA released its second quarter 2025 financial results, revealing "a six-month backlog in unpaid provider claims for Recell proced. ...